The Hemodynamic Effects of Adrenergic Blocking Agents

Total Page:16

File Type:pdf, Size:1020Kb

The Hemodynamic Effects of Adrenergic Blocking Agents CURRENT DRUG THERAPY * DONALD G. VIDT, MD, AND ALAN BAKST, PharmD, EDITORS The hemodynamic effects of adrenergic blocking agents PROFESSOR PER LUND-JOHANSEN • The various antihypertensive agents reduce blood pressure by different mechanisms. Alpha-1 receptor blockers reduce vascular resistance and maintain cardiac output. Chronic treatment with beta blockers without intrinsic sympathomimetic activity produces a fall in blood pressure which is as- sociated with a fall in cardiac index and heart rate. Beta blockers with strong intrinsic sym- pathomimetic activity showed reduced heart rate during exercise. Labetalol reduces cardiac output and peripheral vascular resistance with little or no reduction in peripheral blood flow. Alpha-1 blockers are suitable for patients with active life-styles, with peripheral vascular disorders, or with high blood- cholesterol levels. Beta blockers are useful in patients who have tachycardia, palpitation problems, or angina pectoris, or who have survived a heart attack. They should not be used in patients with bronchial asthma, reduced peripheral blood flow, or heart failure. Labetalol reduces blood pressure in a somewhat larger fraction of patients than the pure alpha- or beta-blocking agents. It is hoped that its long-term results will include regression of cardiovascular damage, improved quality of life, and increased life expectancy. • INDEX TERMS: HEMODYNAMICS; HYPERTENSION; ADRENERGIC ALPHA RECEPTOR BLOCKERS; ADRENERGIC BETA RECEPTOR BLOCKERS • CLEVE CLIN ] MED 1992; 59:193-200 HE MAJOR hemodynamic factors control- In the early stages of hypertension, the sympathetic ling blood pressure are cardiac output and nervous system is overactive.4 Young subjects with total peripheral resistance. Hemodynamic mild hypertension have a characteristic hemodynamic alterations in hypertension differ in the early pattern during rest of high cardiac output, rapid heart Tand later stages of the disorder.1,2 In a 20-year follow-up rate, normal stroke volume, and total peripheral resis- study of 76 hypertensive patients, we demonstrated tance not different from normotensive controls. hemodynamic changes over time from a pattern of During exercise, however, the increase of the stroke high cardiac output and low resistance in young volume is limited, and although the heart rate tends to patients, to a pattern of low cardiac output and high be fast, cardiac output during submaximal exercise is resistance in older patients (Figure J).3 slightly reduced. Total peripheral resistance during ex- ercise does not fall to the same low levels found in From the Section of Cardiology, Haukeland Hospital, Bergen. normotensive controls. Address reprint requests to P.L-J., Section of Cardiology, Medical As the hypertensive patient grows older, structural Department, Haukeland Hospital, 5021 Bergen, Norway. changes in the heart and in the arterioles are probably This article was produced by Consultants in Medical Education, responsible for maintaining increased blood pressure. Inc., Manhasset, New York, under an educational grant from Schering-Plough International. In most patients over age 40 with established hyper- MARCH • APRIL 1992 CLEVELAND CLINIC JOURNAL OF MEDICINE 193 Downloaded from www.ccjm.org on October 1, 2021. For personal use only. All other uses require permission. ADRENERGIC BLOCKERS • LUND-JOHANSEN commonly used antihyper- TPRI dyn s cnr5rrr2 HR beats/min tensive drugs. BP mmHg 4000 I- 6 EFFECTS OF ALPHA BLOCKERS 200 SAP 150 3000 - * 180 Alpha receptors in the 100 2000 peripheral blood vessels mediate sympathetic nerve 160 60 1000 stimulation and are impor- SI mL stroke"1 rrr2 CI L min-1m-2 tant for the regulation of 140 the local blood flow and for 70 10 the control of total periph- 120 eral resistance and, there- 50 by, the blood pressure. For 100 several decades, attempts 30 have been made to reduce Í—1—I I 1—1 I I I I I I—I—I I I I I the effect of increased sym- 1000 500 1000 500 1000 500 pathetic tone on the resis- 2 2 2 V02 mLymin-Vrrr VOp mUmin-Vm- V02 mL/min-Vm- tance vessel by using alpha blockade. The first alpha FIGURE 1. Hemodynamic alterations in essential hypertension over 20 years.3 Age at initial blockers were nonspecific study 17-29 yrs. Mean values and SEM. VO2, oxygen consumption; HR, heart rate; CI, car- and blocked both alpha-1 diac index; SI, stroke index; SAP, systolic arterial pressure; MAP, mean arterial pressure; and alpha-2 receptors at DAP, diastolic arterial pressure; TPRI, total peripheral resistance index. the nerve terminal and at the effector cells. Such tension, the characteristic hemodynamic pattern drugs (eg, phenoxybenzamine, dibenzyline) induced during rest is normal cardiac output and increased total vasodilatation, but when blood pressure fell, heart rate peripheral resistance. During exercise, cardiac output is and cardiac output increased markedly. Consequently, subnormal and total peripheral resistance is markedly the fall in blood pressure was modest, and these drugs elevated. could not be used for long-term treatment.12 In the later stages of severe essential hypertension, The situation changed completely when selective total peripheral resistance is greatly increased at rest alpha-1 receptor blockers were developed. These left and during exercise, often to more than twice the the alpha-2 receptors undisturbed, thus preserving the upper normal value. Heart pump function is markedly negative feedback system for noradrenalin at the nerve reduced with a fall in stroke volume when exercise load terminal. This produced vasodilatation without reflex increases. tachycardia.12'14 During the last decades of life, abnormalities in the heart are seen, including reduced compliance, reduced Acute and long-term effects filling rate, increased left ventricular thickness, and When an alpha-1 receptor blocker like doxazosin is left ventricular mass.5 Disturbances in the diastolic injected as a single dose, total peripheral resistance falls function probably are the first to occur. Recent echo- rapidly, with no significant changes in heart rate or Doppler studies also have demonstrated reduced pump cardiac output. This results in an immediate fall in function during exercise.6 The increased vascular resis- blood pressure, which is seen at rest and during exer- tance is found in most vascular beds, although to vary- cise.10 In some patients, the fall in blood pressure is ing degrees.7 excessive, and in ambulatory patients this can induce The various antihypertensive agents reduce blood the so-called "first-dose syncope reaction." In our series pressure by very different mechanisms. Drugs which on doxazosin, 3 of 15 patients had a marked reduction act via the adrenergic receptors may induce widely in vascular resistance and blood pressure in the supine different hemodynamic changes at rest and during ex- position after 1 mg of doxazosin was given intravenous- ercise.8*11 The following discussion briefly reviews the ly, while heart rate did not increase. When the dose was short- and long-term hemodynamic effects of these reduced, these hypotensive reactions were not seen.10 194 CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 59 NUMBER 2 Downloaded from www.ccjm.org on October 1, 2021. For personal use only. All other uses require permission. ADRENERGIC BLOCKERS • LUND-JOHANSEN Our 1974 study14 dem- CI Umin-Vm-2 onstrated that prazosin in- 10 MAP mmHg duced normalization of TPRI dyn sec cm-5rrr2 central hemodynamics at 150 rest and during exercise (Figure 2). Significant reduction in total periph- 100 eral resistance was seen in 500 1000 500 1000 500 1000 2 V02 mUmirrVnr all patients. Blood pressure was reduced about 10% in HR x MAP beats/min mmHg HR beats/min patients with mild to 28000 moderately severe essential SI mL/stroke-Vnr2 hypertension. Heart rate 150 20000 did not change significant- y * ly, while exercise stroke index increased. As a con- 100 10000 sequence, the post-treat- 4000 500 1000 ment cardiac index was 500 1000 500 1000 higher than before treat- V O. , mLVmin-Vm-2 ment, inducing better total blood flow and normaliza- FIGURE 2. Central hemodynamics at rest and during exercise before (solid line) and during tion of arteriovenous (broken line)) 1 year treatment with prazosin (N=10). Mean values and SEM. *P < 0.05, **fP oxygen difference. Our < 0.01, ***P < 0.001. V02, oxygen consumption; HR, heart rate; CI, cardiac index; SI, more recent studies on stroke index; MAP, mean arterial pressure; TPRI, total peripheral resistance index. doxazosin and trimazosin have found the same effects.10,13 Our data have been output was counteracted by a 20% increase in total supported by studies from several other laboratories.12 peripheral resistance index. During the following 5 hours, total peripheral resistance fell towards pretreat- EFFECTS OF BETA BLOCKERS ment levels (for reasons still not quite understood), and the negative inotropic effect disappeared. The The hemodynamic changes induced by beta blockers negative chronotropic effect was still present after 4 are different in the acute stage compared with long- hours, when the fall in blood pressure was equivalent term use, and are different for beta blockers with vs to the reduction in cardiac index.18 without intrinsic sympathomimetic activity (ISA).9,15,16 With other beta blockers (eg, timolol, atenolol), the blood pressure fall after 4 to 5 hours is usually greater Acute effect than that achieved with epanolol.15 The classic study of Tarazi and Dustan in 197217 showed that, when propranolol was injected in a single Chronic effect dose, the initial response was a marked reduction in The typical response to chronic (1-year) treatment heart rate and cardiac output, a reflex increase in total with beta blockers without ISA is a fall in blood pres- peripheral resistance, and little immediate effect on sure at rest of about 15% to 20%, associated with a fall the blood pressure. But after 8 months, peripheral resis- in cardiac index and heart rate of approximately tance had fallen while cardiac output remained 25%.9,15 With cardioselective drugs such as atenolol reduced and blood pressure fell.
Recommended publications
  • Drug Class Review Beta Adrenergic Blockers
    Drug Class Review Beta Adrenergic Blockers Final Report Update 4 July 2009 Update 3: September 2007 Update 2: May 2005 Update 1: September 2004 Original Report: September 2003 The literature on this topic is scanned periodically. The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use, or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Mark Helfand, MD, MPH Kim Peterson, MS Vivian Christensen, PhD Tracy Dana, MLS Sujata Thakurta, MPA:HA Drug Effectiveness Review Project Marian McDonagh, PharmD, Principal Investigator Oregon Evidence-based Practice Center Mark Helfand, MD, MPH, Director Oregon Health & Science University Copyright © 2009 by Oregon Health & Science University Portland, Oregon 97239. All rights reserved. Final Report Update 4 Drug Effectiveness Review Project TABLE OF CONTENTS INTRODUCTION .......................................................................................................................... 6 Purpose and Limitations of Evidence Reports........................................................................................ 8 Scope and Key Questions .................................................................................................................... 10 METHODS.................................................................................................................................
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Medication for Military Aircrew: Current Use, Issues
    RTO-TR-014 AC/323(HFM-014)TP/14 NORTH ATLANTIC TREATY ORGANIZATION RTO-TR-014 RESEARCH AND TECHNOLOGY ORGANIZATION BP 25, 7 RUE ANCELLE, F-92201 NEUILLY-SUR-SEINE CEDEX, FRANCE RTO TECHNICAL REPORT 14 Medication for Military Aircrew: Current Use, Issues, and Strategies for Expanded Options (les M´edicaments pour les equipages´ militaires : Consommation actuelle, questions et strat´egies pour des options elargies)´ Report of the Human Factors and Medicine Panel (HFM) Working Group 26. Published June 2001 Distribution and Availability on Back Cover 7KLVSDJHKDVEHHQGHOLEHUDWHO\OHIWEODQN 3DJHLQWHQWLRQQHOOHPHQWEODQFKH RTO-TR-014 AC/323(HFM-014)TP/14 NORTH ATLANTIC TREATY ORGANIZATION RESEARCH AND TECHNOLOGY ORGANIZATION BP 25, 7 RUE ANCELLE, F-92201 NEUILLY-SUR-SEINE CEDEX, FRANCE RTO TECHNICAL REPORT 14 Medication for Military Aircrew: Current Use, Issues, and Strategies for Expanded Options (les M´edicaments pour les equipages´ militaires : Consommation actuelle, questions et strat´egies pour des options elargies)´ Authors: EDIGER Mark, M.D. (US) Working Group Chairman BENSON, Alan J. (UK), DANESE, Daniele (IT), DAVIDSON, Ronald A., (CA), DOIREAU, Philippe (FR), ELIOPOULOS, Themis (GR), GRAY, Gary W. (CA), LAM, Berry (NL), NICHOLSON, Anthony A., (UK), PARIS, Jean-Fran¸cois, (FR), PICKARD, Jeb S., (US), PIERARD, C. (FR) Co-Authors: GOURBAT, Jean-Pierre (FR), LAGARDE, D. (FR), LALLEMENT G., (FR), PERES, M. (FR), RODIG,¨ E. (GE), STONE, Barbara M. (UK), TURNER, Claire (UK) Report of the Human Factors and Medicine Panel (HFM) Working Group 26. The Research and Technology Organization (RTO) of NATO RTO is the single focus in NATO for Defence Research and Technology activities. Its mission is to conduct and promote cooperative research and information exchange.
    [Show full text]
  • A Study on Beta Blockers - a Brief Review Tv
    IJRPC 2018, 8(4), 508-529 Namratha et al. ISSN: 22312781 INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY Available online at www.ijrpc.com Review Article A STUDY ON BETA BLOCKERS - A BRIEF REVIEW TV. Namratha*, KC. Chaluvaraju and AM. Anushree Department of Pharmaceutical Chemistry, Government College of Pharmacy, Bengaluru-560 027, Karnataka, India. ABSTRACT Beta blockers are agents or drugs which competitively inhibit the action of catecholamines at the beta adrenergic receptors, which are mainly used to treat variety of clinical conditions like angina, hypertension, asthma, COPD and arrhythmias. These drugs are also useful in several other therapeutic situations including shock, premature labor and opioid withdrawal, and as adjuncts to general anesthetics. These drugs produce their effect by interacting with the beta adrenergic receptors. In the present communication, an effort has been made to compile beta adrenergic receptors and the chemistry, discovery and development, classification and therapeutic applications of beta blockers. Keywords: Beta blockers, adrenergic receptors, catecholamines and aryloxypropanolamines. 1. INTRODUCTION Beta blockers were first developed by Sir 1.1 Adrenergic receptors James Black in 1962. The structures of The ability of a molecule to selectively these receptors have been studied by x- agonize or antagonize adrenergic ray crystallography.5 In the current article receptor made great advances in beta blockers are majorly focused with pharmacotherapeutics. The discovery of respect to their location, functions adrenergic receptors lead to major mediated, discovery and development, development of newer adrenergic SAR, classification, structures and agonists as well as antagonist.1 therapeutic applications. Adrenergic receptors are 7- transmembrane spanning receptors 1.2 Locations and agonistic action of beta which mediate both central and adrenergic receptors6 peripheral actions of the adrenergic The following are the various beta neurotransmitters.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • SUPPLEMENTARY MATERIAL 1: Search Strategy
    SUPPLEMENTARY MATERIAL 1: Search Strategy Medline search strategy 1. exp basal ganglia hemorrhage/ or intracranial hemorrhages/ or cerebral hemorrhage/ or intracranial hemorrhage, hypertensive/ or cerebrovascular disorders/ 2. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or intraparenchymal or intraventricular or infratentorial or supratentorial or basal gangli$ or putaminal or putamen or posterior fossa or hemispher$ or pon$ or lentiform$ or brainstem or cortic$ or cortex$ or subcortic$ or subcortex$) adj5 (h?emorrhag$ or h?ematoma$ or bleed$)).tw 3. ((hemorrhag$ or haemorrhag$) adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva)).tw 4. (ICH or ICHs or PICH or PICHs).tw 5. 1 or 2 or 3 or 4 6. exp blood pressure/ 7. exp hypertension/ 8. (blood pressure or bloodpressure).tw 9. ((bp or blood pressure) adj5 (lowering or reduc$)).tw 10. ((strict$ or target$ or tight$ or intens$ or below) adj3 (blood pressure or systolic or diastolic or bp or level$)).tw 11. (hypertension or hypertensive).tw 12. ((manage$ or monitor$) adj3 (hypertension or blood pressure)).tw 13. ((intense or intensive or aggressive or accelerated or profound or radical or severe) adj5 ((bp or blood pressure) adj5 (lowering or reduc$ or decreas$ or decrement or dimin$ or declin$))).tw 14. ((standard or normal or ordinary or guideline or guide line or guideline recommend$ or recommend$ or convention$ or usual or established) adj5 ((bp or blood pressure) adj5 (lowering or reduc$ or decreas$ or decrement or dimin$ or declin$))).tw 15. (antihypertensive adj2 (agent$ or drug$ or medicat$)).tw 1 16. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 17.
    [Show full text]
  • Pharmacotherapy for Mild Hypertension (Review) – the Cochrane Collaboration
    Pharmacotherapy for mild hypertension (Review) Diao D, Wright JM, Cundiff DK, Gueyffier F This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2012, Issue 11 http://www.thecochranelibrary.com Pharmacotherapy for mild hypertension (Review) Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. T A B L E O F C O N T E N T S HEADER ....................................... 1 ABSTRACT ...................................... 1 PLAIN LANGUAGE SUMMARY .............................. 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . 2 BACKGROUND .................................... 5 OBJECTIVES ..................................... 5 METHODS ...................................... 5 RESULTS ....................................... 6 Figure 1. ..................................... 7 DISCUSSION ..................................... 8 Figure 2. ..................................... 9 AUTHORS’ CONCLUSIONS ............................... 10 ACKNOWLEDGEMENTS ................................ 10 REFERENCES ..................................... 10 CHARACTERISTICS OF STUDIES ............................. 13 DATA AND ANALYSES .................................. 19 Analysis 1.1. Comparison 1 Treatment versus No Treatment, Outcome 1 Mortality. 19 Analysis 1.2. Comparison 1 Treatment versus No Treatment, Outcome 2 Stroke. 20 Analysis 1.3. Comparison 1 Treatment versus No Treatment, Outcome 3 Coronary Heart Disease. 20 Analysis 1.4. Comparison 1 Treatment versus
    [Show full text]
  • Pharmacokinetics of Epanolol After Acute Andchronic Oral Dosing In
    Br. J. clin. Pharmac. (1990), 29, 333-337 Pharmacokinetics of epanolol after acute and chronic oral dosing in elderly patients with stable angina pectoris J. HOSIE', A. K. SCOPE2, J. C. PETRIE2 & I. D. COCKSHO1T3 'The Surgery, 1980 Great Western Road, Glasgow, G13 2SW, 2Clinical Pharmacology Unit, University of Aberdeen, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, AB9 2ZB and 3Safety of Medicines Department, ICI Pharmaceuticals, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG 1 Epanolol is a novel anti-anginal agent which is a 1 1-adrenoceptor partial agonist exhibiting selective 1l-adrenoceptor antagonist and selective 1l-adrenoceptor agonist activity. It is mainly metabolised to conjugates prior to excretion in urine and it was of interest to determine if any accumulation occurred in elderly patients. 2 The pharmacokinetics of epanolol have been studied over 72 h after a single oral dose of 200 mg and then over 24 h after 12 consecutive daily oral doses in 13 elderly patients with stable angina pectoris. 3 The peak plasma concentrations (mean ± s.d.) after the single dose (25.7 ± 17.0 ng ml-) were not significantly different (P = 0.35) from those at steady state (32.4 ± 20.9 ng ml-'). There was wide inter-individual variation on both occasions. The time to peak did not alter significantly during the study with mean values of 1.5 and 1.2 h on acute and chronic dosing respectively. 4 Plasma concentrations declined biphasically with a mean terminal phase half-life of 17 h and 5 fold inter-individual variation. 5 The mean area under the curve to 24 h was not significantly different (P = 0.26) after the single dose (59.0 ± 29.8 ng ml-' h) from that at steady state (78.4 ± 55.0 ng ml-1 h).
    [Show full text]
  • Effects of Pharmacological Exposure on Ovarian Cancer (EPOC)
    Sharp et al. Ovarian Pharmacoepidemiology ENCePP Protocol Effects of pharmacological exposure on Ovarian Cancer (EPOC) PROTCOL & ANALYSIS PLAN Project funded by Health Research Board Date: 01/08/2014 Version: V1.0 V1.0 PUBLIC ©NCRI 2014 Page 1 of 28 Sharp et al. Ovarian Pharmacoepidemiology ENCePP Protocol 1. Project Synopsis Project Title: Translating basic science into improved patient outcomes in ovarian cancer: an Ireland-UK collaboration investigating common pharmacological exposures and tumour characteristics, recurrence, survival and mortality. Research theme: Pharmacoepidemiology NCRI Staff Members: Mr Chris Brown, Dr Linda Sharp Funding source: Health Research Board Project duration: 2013 - 2015 Project Overview: By combining data from large pharmacoepidemiology databases in Ireland and the UK, will conduct a population-based study investigating associations between use of statins, beta-blockers and NSAIDs and ovarian cancer progression and outcome. This study will provide valuable population-based evidence on the effects of these common drugs on ovarian cancer and contribute to improved health outcomes for women affected by this cancer. Investigators: Dr Kathleen Bennett, Pharmacology & Therapeutics, Trinity College, St James’s Hospital Dublin Dr Thomas Ian Barron, Department of Pharmacology & Therapeutics, Trinity College Dublin Prof Liam Murray, Centre for Public Health, Queen’s University Belfast Dr John Coulter, Gynaecological Oncology, South Infirmary Victoria University Hospital, Cork Collaborators: Prof Carmel Hughes,
    [Show full text]